Burning Rock Biotech (NASDAQ:BNR) Trading 0.1% Higher – Still a Buy?

Burning Rock Biotech Limited (NASDAQ:BNR) shares shot up 0.1% during mid-day trading on Tuesday . The stock traded as high as $7.39 and last traded at $7.06. 8,916 shares were traded during mid-day trading, an increase of 79% from the average session volume of 4,979 shares. The stock had previously closed at $7.05.

Burning Rock Biotech Stock Performance

The stock has a market capitalization of $72.32 million, a P/E ratio of -2.35 and a beta of 0.55. The stock’s 50 day simple moving average is $5.63 and its 200 day simple moving average is $5.28.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Burning Rock Biotech stock. SkyView Investment Advisors LLC acquired a new position in shares of Burning Rock Biotech Limited (NASDAQ:BNR) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 10,000 shares of the company’s stock, valued at approximately $64,000. SkyView Investment Advisors LLC owned 0.10% of Burning Rock Biotech as of its most recent SEC filing. Hedge funds and other institutional investors own 30.03% of the company’s stock.

Burning Rock Biotech Company Profile

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.